Literature DB >> 28178250

Spinal muscular atrophy approval boosts antisense drugs.

Elie Dolgin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28178250     DOI： 10.1038/nbt0217-99

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Antisense--down, but not out.

Authors:  Carol Potera
Journal:  Nat Biotechnol       Date:  2007-04-30       Impact factor: 54.908

2.  Big win possible for Ionis/Biogen antisense drug in muscular atrophy.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2016-10-11       Impact factor: 54.908

3.  Antisense battles small molecule for slice of rare lipid disorder market.

Authors:  Gunjan Sinha
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908

4.  Nature Biotechnology's academic spinouts of 2015.

Authors:  Aaron Bouchie; Laura DeFrancesco
Journal:  Nat Biotechnol       Date:  2016-05-06       Impact factor: 54.908
  4 in total
  8 in total

Review 1.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

2.  Drugmakers accused of exploiting orphan drug incentives, fueling price problem.

Authors:  Brady Huggett
Journal:  Nat Biotechnol       Date:  2017-04-11       Impact factor: 54.908

3.  An Evidence-Based, Community-Engaged Approach to Develop an Interactive Deliberation Tool for Pediatric Neuromuscular Trials.

Authors:  Rebecca R Moultrie; Megan A Lewis; Ryan S Paquin; Ann Lucas; Jill Jarecki; Holly L Peay
Journal:  J Genet Couns       Date:  2017-12-20       Impact factor: 2.537

4.  Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1.

Authors:  Siham Ait Benichou; Dominic Jauvin; Thiéry De Serres-Bérard; Marion Pierre; Karen K Ling; C Frank Bennett; Frank Rigo; Genevieve Gourdon; Mohamed Chahine; Jack Puymirat
Journal:  Gene Ther       Date:  2022-01-25       Impact factor: 5.250

5.  RNA-As-Graphs Motif Atlas-Dual Graph Library of RNA Modules and Viral Frameshifting-Element Applications.

Authors:  Qiyao Zhu; Louis Petingi; Tamar Schlick
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

6.  LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts.

Authors:  Aleksander Touznik; Rika Maruyama; Kana Hosoki; Yusuke Echigoya; Toshifumi Yokota
Journal:  Sci Rep       Date:  2017-06-16       Impact factor: 4.379

7.  Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice.

Authors:  Dominic Jauvin; Jessina Chrétien; Sanjay K Pandey; Laurie Martineau; Lucille Revillod; Guillaume Bassez; Aline Lachon; A Robert MacLeod; Geneviève Gourdon; Thurman M Wheeler; Charles A Thornton; C Frank Bennett; Jack Puymirat
Journal:  Mol Ther Nucleic Acids       Date:  2017-05-17

Review 8.  Advances in the delivery of RNA therapeutics: from concept to clinical reality.

Authors:  James C Kaczmarek; Piotr S Kowalski; Daniel G Anderson
Journal:  Genome Med       Date:  2017-06-27       Impact factor: 11.117
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.